About Chugai
Chugai's mission is to create innovative drugs
for the benefit of patients.
News ReleasesRSS
- Jul 13, 2020 New Interim Results from Phase IIIb Study Reinforce the Long-Term Safety Profile of Chugai’s Hemlibra in Hemophilia A
- Jul 13, 2020 Chugai Provides Update on the Phase III IMagyn050 study of Tecentriq in Combination with Chemotherapy and Avastin as a Treatment of Newly-Diagnosed Ovarian Cancer
- Jul 09, 2020 Results of Maruho’s Phase III Study with Chugai’s Nemolizumab for Atopic Dermatitis Published in The New England Journal of Medicine Online
- Jun 30, 2020 Chugai Files a New Drug Application for Polatuzumab Vedotin for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Jun 29, 2020 Chugai’s Enspryng (Satraliazumab) Subcutaneous Injection 120 mg Syringe Approved in Japan for Neuromyelitis Optica Spectrum Disorder
-
Human Resources and Diversity & Inclusion
Find information on our initiatives to promote work-life balance and diverse human resources, and performance data for topics such as the ratio of female employees.
-
Personnel Systems
Chugai promotes engagement with employees by conducting talent management according to each person’s capabilities and aptitude, providing systems that help our diverse people to succeed, and creating supportive work environments.
For more information
Feature: Chugai’s Sustainability Activities
Recent Social Contribution Activities
-
Wheelchair Softball Trail Session
-
Contribution to Global Environmental Protection - Efforts to protect water resources through forest maintenance at our production site -
-
Workshop on Multidisciplinary Team Care in Cambodia
